

Resource Summary Report

Generated by T1D on Aug 9, 2026

Thermo Fisher: Sartorius: IncuCyte S3 Live Cell Analysis System

RRID:SCR_023147

Type: Tool

Proper Citation

Thermo Fisher: Sartorius: IncuCyte S3 Live Cell Analysis System (RRID:SCR_023147)

Resource Information

URL: <https://www.sartorius.com/en/products/live-cell-imaging-analysis/live-cell-analysis-instruments/s3-live-cell-analysis-instrument#id-797316>

Proper Citation: Thermo Fisher: Sartorius: IncuCyte S3 Live Cell Analysis System (RRID:SCR_023147)

Description: System that automatically captures and analyzes images of living cells around-the-clock for days, weeks, or months, while cells remain undisturbed inside standard tissue culture incubator. Kinetic, image-based measurements. Used for cell monitoring and surveillance, cell health and viability, migration and invasion, phenotypic cell based assays.

Synonyms: Incucyte Live-Cell Analysis System, Incucyte S3 Live-Cell Analysis Instrument, Incucyte S3 System

Resource Type: instrument resource

Keywords: Instrument, Equipment, USEDit, Sartorius AG, living cells images, automatically capture and analyze images,

Resource Name: Thermo Fisher: Sartorius: IncuCyte S3 Live Cell Analysis System

Resource ID: SCR_023147

Record Creation Time: 20230118T050205+0000

Record Last Update: 20260808T190242+0000

Ratings and Alerts

No rating or validation information has been found for Thermo Fisher: Sartorius: IncuCyte S3 Live Cell Analysis System.

No alerts have been found for Thermo Fisher: Sartorius: IncuCyte S3 Live Cell Analysis System.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 77 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#).

Aggrey-Fynn JE, et al. (2026) Epigenetic context defines the transcriptional activity of canonical and noncanonical NF- κ B signaling in pancreatic cancer. Cell death discovery, 12(1).

Thienger P, et al. (2026) A Double-Negative Prostate Cancer Subtype Is Vulnerable to SWI/SNF-Targeting Degradable Molecules. Cancer research, 86(7), 1570.

Zeng Z, et al. (2026) Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancer. British journal of cancer, 134(12), 1830.

Mrkacek M, et al. (2026) ORMDL Proteins Turnover via Proteasome and Autophagy Is Cell-Type Dependent and Tied to Ceramide Homeostasis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 40(6), e71655.

Davi V, et al. (2026) Endoplasmic Reticulum Geometry Dictates Neuronal Bursting via Calcium Store Refill Rates and Exposes Selective Neuronal Vulnerability. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(36), e21101.

Fang C, et al. (2026) Base Editing of TIGIT Reprograms CD155 Signaling in Natural Killer Cells to Enhance Cancer Immunotherapy Efficacy. Cancer research, 86(8), 1956.

Grace E, et al. (2026) Metabolic plasticity and optimal redox homeostasis are essential for efficient metastatic colonization. Molecular metabolism, 109, 102382.

Lin P, et al. (2026) CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models. Blood cancer discovery, 7(2), 234.

McDonald TO, et al. (2026) BESTDR Enables Bayesian Quantification of Mechanism-Specific Drug Responses. Cancer research, 86(5), 1286.

Esapa B, et al. (2026) An antibody-drug conjugate designed through clone and isotype selection restricts the growth of CSPG4-expressing triple-negative breast cancer. NPJ

precision oncology, 10(1).

Nigri J, et al. (2026) Myofibroblasts Induce Neuroplasticity to Promote Pancreatic Inflammation and Cancer Progression. *Cancer discovery*, 16(5), 1014.

Gong D, et al. (2026) GLIS3 marks a neural-like progenitor cell state that drives metastasis in pancreatic ductal adenocarcinoma. *Cell reports*, 45(5), 117314.

Shah UA, et al. (2026) A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model. *Cancer discovery*, 16(4), 697.

Yapindi L, et al. (2026) Dual Inhibition of TRIP13 and Aurora A Induces Mitotic DNA Damage and Concurrent Pyroptotic-Apoptotic Cell Death in Rb-Deficient Cancer Cells. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(14), 3043.

Li N, et al. (2026) Development of Glypican 3-Targeting Antibody-Drug Conjugates for Hepatocellular Carcinoma Therapy. *Cancer research communications*, 6(7), 1665.

Singh D, et al. (2026) Antibody-Mediated Targeting of Secretory Protein SCUBE3 Suppresses Cancer Progression by Inhibiting Oncogenic Signaling and Inducing Antitumor Immunity. *Cancer research*, 86(5), 1252.

Burchett R, et al. (2026) A Universal Boosting Strategy for Adoptive T-cell Therapy Using a Paired Vaccine/Chimeric Antigen Receptor. *Cancer immunology research*, 14(2), 261.

Boudjadi S, et al. (2026) Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma. *Molecular cancer therapeutics*, 25(3), 493.

Zink A, et al. (2026) Pluripotent stem-cell-based screening uncovers sildenafil as a mitochondrial disease therapy. *Cell*, 189(6), 1656.

Laforêts F, et al. (2026) Matrix structure and microenvironment dynamics correlate with chemotherapy response in ovarian cancer. *iScience*, 29(3), 114858.